What is the clinical evidence from this study?

Study design: Editorial. Population: Obstructive hypertrophic cardiomyopathy. Intervention: Surgical septal myectomy vs. Cardiac myosin inhibitors.

January 31, 2026Indian Journal of Thoracic and Cardiovascular Surgery0 citationsOpen Access

Brave new drugs, enduring old skills: why surgery still matters in the cardiac myosin inhibitor era

HAHisham AhamedAmrita Institute of Medical Sciences and Research Centre PVPraveen Kerala VarmaAmrita Institute of Medical Sciences and Research Centre

Key Result

Surgical septal myectomy remains an essential and complementary therapy to cardiac myosin inhibitors for selected patients with obstructive hypertrophic cardiomyopathy.

Structured PICO

Population

Patients with obstructive hypertrophic cardiomyopathy (oHCM)

Intervention

Surgical septal myectomy and cardiac myosin inhibitors (mavacamten, aficamten)

Despite the advent of cardiac myosin inhibitors, surgical septal myectomy remains a definitive and essential therapy for specific subsets of patients with obstructive hypertrophic cardiomyopathy.

Limitations

Substantial safety and monitoring requirements for cardiac myosin inhibitors
Drug-drug interactions complicate therapy
Cost and access are major constraints
Limited long-term outcome data for continuous myosin inhibition

KI fragen

Bookmark

View Full Paper

KI fragen

Bookmark

View Full Paper

Cite This Study

Ahamed et al. (Fri,) conducted a editorial in Obstructive hypertrophic cardiomyopathy. Surgical septal myectomy vs. Cardiac myosin inhibitors was evaluated. Surgical septal myectomy remains an essential and complementary therapy to cardiac myosin inhibitors for selected patients with obstructive hypertrophic cardiomyopathy.

synapsesocial.com/papers/6a0258fb45880192ae423cd4 https://doi.org/https://doi.org/10.1007/s12055-025-02167-4